**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1- 9 (Canceled).

Claim 10. (Previously presented): A method of treating a functional motility disorder of the viscera in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I



I

in free form or in the form of a pharmaceutically acceptable salt, wherein

$R^1$ is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, $C_1$-$C_7$-alkyl, trifluoromethyl, hydroxy and $C_1$-$C_7$-alkoxy;

$R^2$ is hydrogen or $C_1$-$C_7$-alkyl;

$R^3$ is hydrogen, $C_1$-$C_7$-alkyl or phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, $C_1$-$C_7$-alkyl, trifluoromethyl, hydroxy and $C_1$-$C_7$-alkoxy;

$R^4$ is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, $C_1$-$C_7$-alkyl, trifluoromethyl, hydroxy and $C_1$-$C_7$-alkoxy; or is naphthyl, 1H-indol-3-yl or 1-$C_1$-$C_7$-alkyl-indol-3-yl;

$R^5$ and $R^6$ are each independently of the other hydrogen or $C_1$-$C_7$-alkyl, at least one of $R^5$ and $R^6$ being hydrogen; and

$R^7$ is $C_3$-$C_8$-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 11. (Currently amended): A method according to claim ~~1~~10, in which the compound of formula I is of formula IA



IA

in free form or in the form of a pharmaceutically acceptable salt,

where * denotes the R configuration; ~~and $R^1$, $R^2$, $R^3$, $R^4$, $R^5$, $R^6$ and $R^7$ are as defined in claim 1~~

$R^1$ is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, $C_1$-$C_7$-alkyl, trifluoromethyl, hydroxy and $C_1$-$C_7$-alkoxy;

$R^2$ is hydrogen or $C_1$-$C_7$-alkyl;

$R^3$ is hydrogen, $C_1$-$C_7$-alkyl or phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, $C_1$-$C_7$-alkyl, trifluoromethyl, hydroxy and $C_1$-$C_7$-alkoxy;

$R^4$ is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, $C_1$-$C_7$-alkyl, trifluoromethyl, hydroxy and $C_1$-$C_7$-alkoxy; or is naphthyl, 1H-indol-3-yl or 1-$C_1$-$C_7$-alkyl-indol-3-yl;

$R^5$ and $R^6$ are each independently of the other hydrogen or $C_1$-$C_7$-alkyl, at least one of $R^5$ and $R^6$ being hydrogen; and

$R^7$ is $C_3$-$C_8$-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 12. (Currently amended): A method according to claim ~~1~~10, in which

$R^1$ is phenyl, 3,5-bistrifluoromethyl-phenyl or 3,4,5-trimethoxyphenyl;

$R^2$ is hydrogen or $C_1$-$C_7$-alkyl;

$R^3$ is hydrogen or phenyl;

$R^4$ is phenyl, halo-phenyl, dihalo-phenyl, trihalo-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-$C_1$-$C_7$-alkyl-indol-3-yl;

$R^5$ and $R^6$ are each independently of the other hydrogen or $C_1$-$C_7$-alkyl, at least one of $R^5$ and $R^6$ being hydrogen; and

$R^7$ is $C_5$-$C_7$cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 13. (Currently amended): A method according to claim ~~2~~11, in which

$R^1$ is phenyl, 3,5-bistrifluoromethyl-phenyl or 3,4,5-trimethoxyphenyl;

$R^2$ is hydrogen or $C_1$-$C_7$-alkyl;

$R^3$ is hydrogen or phenyl;

$R^4$ is phenyl, halo-phenyl, dihalo-phenyl, trihalo-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-$C_1$-$C_7$-alkyl-indol-3-yl;

$R^5$ and $R^6$ are each independently of the other hydrogen or $C_1$-$C_7$-alkyl, at least one of $R^5$ and $R^6$ being hydrogen; and

$R^7$ is $C_5$-$C_7$cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 14. (Currently amended): A method according to claim ~~1~~10, in which

$R^1$ is 3,5-bistrifluoromethyl-phenyl;

$R^2$ is hydrogen, methyl or ethyl;

$R^3$ is hydrogen or phenyl;

$R^4$ is phenyl, 4-chlorophenyl, 4-fluorophenyl, 3,4-dichloro-phenyl, 3,4-difluoro-phenyl, 3-fluoro-4-chloro-phenyl, 3,4,5-trifluoro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl;

$R^5$ and $R^6$ are each independently of the other hydrogen or methyl, at least one of $R^5$ and $R^6$ being hydrogen; and

$R^7$ is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 15. (Currently amended): A method according to claim ~~2~~11, in which

$R^1$ is 3,5-bistrifluoromethyl-phenyl;

$R^2$ is hydrogen, methyl or ethyl;

$R^3$ is hydrogen or phenyl;

$R^4$ is phenyl, 4-chlorophenyl, 4-fluorophenyl, 3,4-dichloro-phenyl, 3,4-difluoro-phenyl, 3-fluoro-4-chloro-phenyl, 3,4,5-trifluoro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl;

$R^5$ and $R^6$ are each independently of the other hydrogen or methyl, at least one of $R^5$ and $R^6$ being hydrogen; and

$R^7$ is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 16. (Currently amended): A method according to claim ~~1~~10, in which

$R^1$ is 3,5-bistrifluoromethyl-phenyl;

$R^2$ is hydrogen or methyl;

$R^3$ is hydrogen or phenyl;

$R^4$ is phenyl, 4-chlorophenyl, 3,4-dichloro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl;

$R^5$ and $R^6$ are hydrogen; and

$R^7$ is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 17. (Currently amended): A method according to claim ~~2~~11, in which

$R^1$ is 3,5-bistrifluoromethyl-phenyl;

$R^2$ is hydrogen or methyl;

$R^3$ is hydrogen or phenyl;

$R^4$ is phenyl, 4-chlorophenyl, 3,4-dichloro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl;

$R^5$ and $R^6$ are hydrogen; and

$R^7$ is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 18. (Currently amended): A method according to claim ~~1~~10, in which the compound of formula I is selected from the group consisting of:

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]- amide,

(4R)-(N'-methyl-N'-benzoyl-amino)-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-(N'-methyl-N'-benzoyl)-amino-5-(naphth-2-yl)-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,4,5-trimethoxy-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-difluorobenzyl)-but-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-2-methyl-pent-2-enoic acid N-cyclohexylamide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-2-methyl-but-2-enoic acid [(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-ethyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-3-methyl-pent-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-3-methyl-but-2-enoic acid [(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3-fluoro-4-chlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-difluorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dibromobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4,5-trifluorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-fluorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-[N'-(3,5-bistrifluoromethyl-benzoyl)-N'-methyl-amino]-5,5-diphenyl-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide, and

(4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide.

Claim 19. (Currently amended): A method according to claim ~~1~~10, in which the compound of formula I is a compound of formula II



II

Claim 20. (Withdrawn): A method according to claim 1, in which the functional motility disorder is associated with visceral hypersensitivity or altered motor responses.

Claim 21. (Currently amended): A method according to claim ~~2~~11, in which the functional motility disorder is a functional bowel disorder or a functional gastrointestinal disorder.

Claim 22. (Currently amended): A method according to claim ~~1~~10, in which the functional motility disorder is irritable bowel syndrome ~~or functional dyspepsia~~.

Claim 23. (Currently amended): A method according to claim ~~2~~11, in which the functional motility disorder is irritable bowel syndrome ~~or functional dyspepsia~~.

Claim 24. (Currently amended): A method according to claim 10, in which the functional motility disorder is irritable bowel syndrome ~~or functional dyspepsia~~.

Claim 25. (Currently amended): A method according to claim ~~1~~10, in which the functional motility disorder is diarrhoea-predominant irritable bowel syndrome.

Claim 26. (Previously presented): A method according to claim 10, in which the functional motility disorder is diarrhoea-predominant irritable bowel syndrome.

Claim 27. (Currently amended): A method according to claim ~~1~~10, wherein the effective amount of the compound of formula I is from 1 mg to 1000 mg.

Claim 28. (Currently amended): A method according to claim ~~1~~10, wherein the effective amount of the compound of formula I is from 5 mg to 200 mg.

Claim 29. (Previously presented): A method according to claim 10, wherein the effective amount of the compound of formula IA is from 1 mg to 1000 mg.